OMER NASDAQ
Omeros Corporation
1W: +5.7%
1M: -10.0%
3M: +49.9%
YTD: +6.8%
1Y: +131.7%
3Y: +1322.0%
5Y: +181.2%
$17.49
+1.20 (+7.37%)
Weekly Expected Move ±8.4%
$14
$15
$17
$18
$19
Credit Risk of going bust: higher than 75% of companies Debt: 6.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.27 (down 98%), Omeros Corporation would be worth roughly what it owes.
Total debt $83.8M against a stock market value of $1.27B.
Distance to default 3.00 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $52.3M (short-term plus half of long-term), stock volatility 97.8%; Altman Z'' -4.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.27 (down 98%), Omeros Corporation would be worth roughly what it owes.
Total debt $83.8M against a stock market value of $1.27B.
Distance to default 3.00 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $52.3M (short-term plus half of long-term), stock volatility 97.8%; Altman Z'' -4.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships11
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-30
Earliest Filing
2025-12-01
Latest Filing
partner: 4
acquirer: 3
investor: 3
customer: 1
Counterparties (Filed by OMER)
11 relationshipsCompanies named in OMER's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Novo Nordisk Health Care AG | — | acquirer | Acquired exclusive global rights to develop and commercialize zaltenibart and related assets from Omeros Corporation. | 2025-12-01 | View |
| DRI Health Acquisition LP | — | customer | Licensor of OMIDRIA royalties; receives remitted royalties from Rayner via escrow agent. | 2025-05-15 | View |
| National Institute on Drug Abuse | — | investor | Government funder providing $4.02 million for the Phase 1b clinical trial of OMS527. | 2025-05-15 | View |
| National Institutes of Health | — | investor | Parent organization of the National Institute on Drug Abuse providing funding for the OMS527 trial. | 2025-05-15 | View |
| DRI Healthcare Acquisitions LP | — | partner | Acquired expanded interest in royalties from Omeros' OMIDRIA product | 2024-02-07 | View |
| Rayner Surgical Inc. | — | partner | Original buyer of OMIDRIA assets and current payer of royalties | 2024-02-07 | View |
| DRI Healthcare Acquisitions LP | — | investor | Purchased an interest in royalties from Omeros Corporation's former ophthalmologic product OMIDRIA. | 2022-10-06 | View |
| Rayner Surgical Inc. | — | partner | Original buyer of OMIDRIA assets and current payer of royalties to Omeros Corporation. | 2022-10-06 | View |
| Rayner Surgical Group Limited | — | partner | Co-party in the original Asset Purchase Agreement with Omeros Corporation and Rayner Surgical Inc. | 2022-10-06 | View |
| Rayner Surgical Inc. | — | acquirer | Purchased Omeros Corporation's commercial product OMIDRIA and related assets for approximately $126.0 million in cash. | 2021-12-30 | View |
| Rayner Surgical Group Limited | — | acquirer | Served as the parent guarantor for the asset purchase agreement with Omeros Corporation. | 2021-12-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Officer/Director Change | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-20 | Other Events | View | |
| 2026-07-06 | Other Events | View | |
| 2026-06-25 | Shareholder Vote | View | |
| 2026-06-18 | Other Events | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-31 | Earnings Release; Exhibits | View | |
| 2026-01-07 | Results of Operations and Financial Condition | View | |
| 2025-12-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-01 | Termination of Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Ot | Acquisition | View |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-15 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-02 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-16 | Financial Statements and Exhibits | View | |
| 2025-05-15 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Creation of | Agreement | View |
| 2025-05-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR